Amcad Biomed (ROCO:4188) Cyclically Adjusted Revenue per Share: NT$1.22 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4188 Amcad Biomed Corp ROCO:4188
50 GF Score
Price NT$16.15
GF Value NT$9.65
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Amcad Biomed Cyclically Adjusted Revenue per Share?

Amcad Biomed ROCO:4188 +0.62% 50 Cyclically Adjusted Revenue per Share is NT$1.22 as of Jun. 2026. GuruFocus rates ROCO:4188 with a GF Score™ of 50/100 and a GF Value™ of NT$9.65 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Amcad Biomed's adjusted revenue per share for the three months ended in Jun. 2026 was NT$0.107. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$1.22 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Amcad Biomed's average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Amcad Biomed was 1.20% per year. The lowest was 1.20% per year. And the median was 1.20% per year.

As of today (2026-08-29), Amcad Biomed's current stock price is NT$16.15. Amcad Biomed's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was NT$1.22. Amcad Biomed's Cyclically Adjusted PS Ratio of today is 13.24.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amcad Biomed was 28.73. The lowest was 7.75. And the median was 14.10.


Amcad Biomed  (ROCO:4188) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amcad Biomed's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.15/1.22
=13.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amcad Biomed was 28.73. The lowest was 7.75. And the median was 14.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Amcad Biomed Cyclically Adjusted Revenue per Share Related Terms


Amcad Biomed Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Amcad Biomed's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amcad Biomed Cyclically Adjusted Revenue per Share Chart

Amcad Biomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.14 1.19 1.19 1.18

Amcad Biomed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 1.17 1.18 1.21 1.22

ROCO:4188 vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Amcad Biomed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amcad Biomed Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amcad Biomed's Cyclically Adjusted PS Ratio falls into.


ROCO:4188
50GF Score
Amcad Biomed Corp ROCO:4188
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amcad Biomed Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amcad Biomed's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.107/333.9520*333.9520
=0.107

Current CPI (Jun. 2026) = 333.9520.

Amcad Biomed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.072 241.428 0.100
201612 0.062 241.432 0.086
201703 0.062 243.801 0.085
201706 0.062 244.955 0.085
201709 0.172 246.819 0.233
201712 0.097 246.524 0.131
201803 0.411 249.554 0.550
201806 0.355 251.989 0.470
201809 0.266 252.439 0.352
201812 0.307 251.233 0.408
201903 0.456 254.202 0.599
201906 0.488 256.143 0.636
201909 0.304 256.759 0.395
201912 0.260 256.974 0.338
202003 0.211 258.115 0.273
202006 0.329 257.797 0.426
202009 0.272 260.280 0.349
202012 0.368 260.474 0.472
202103 0.216 264.877 0.272
202106 0.377 271.696 0.463
202109 0.501 274.310 0.610
202112 0.494 278.802 0.592
202203 0.317 287.504 0.368
202206 0.325 296.311 0.366
202209 0.248 296.808 0.279
202212 0.254 296.797 0.286
202303 0.193 301.836 0.214
202306 0.282 305.109 0.309
202309 0.290 307.789 0.315
202312 0.430 306.746 0.468
202403 0.152 312.332 0.163
202406 0.304 314.175 0.323
202409 0.176 315.301 0.186
202412 0.286 315.605 0.303
202503 0.107 319.799 0.112
202506 0.127 322.561 0.131
202509 0.167 324.800 0.172
202512 0.080 324.054 0.082
202603 0.101 330.213 0.102
202606 0.107 333.952 0.107

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$1.22 mean?
Amcad Biomed (ROCO:4188) has a Cyclically Adjusted Revenue per Share of NT$1.22 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amcad Biomed and its competitors.
Is Amcad Biomed's Cyclically Adjusted Revenue per Share too high?
Amcad Biomed's current Cyclically Adjusted Revenue per Share is NT$1.22. Overall, Amcad Biomed has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Amcad Biomed's Cyclically Adjusted Revenue per Share of NT$1.22 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amcad Biomed and its competitors. Amcad Biomed's current Cyclically Adjusted Revenue per Share is NT$1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$9.65, compared to a current price of NT$16.15 — trading 67.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$1.22. Amcad Biomed's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Cyclically Adjusted Revenue per Share is NT$1.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amcad Biomed (ROCO:4188) Overvalued in 2026?

Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued. The current stock price of NT$16.15 is trading 67.4% above its estimated GF Value™ of NT$9.65. GuruFocus considers Amcad Biomed to be Significantly Overvalued.

Key valuation signals for ROCO:4188:

  • Cyclically Adjusted Revenue per Share: NT$1.22
  • GF Value™: NT$9.65 vs. price of NT$16.15 (67.4% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amcad Biomed Business Description

Address Fuxing N. Road, No. 167, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
50GF Score

Get the complete analysis for ROCO:4188

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.15
Price
NT$9.65
GF Value